First Analysis analyst Frank Sparacino upgraded Health Insurance Innovations to Strong Buy with an unchanged price target of $65. Federal regulatory guidance and a proposed rule released last week may provide "further tailwinds" for the company as early as 2020, Sparacino tells investors in a research note. Further, the analyst sees the extension of short-term, limited duration insurance policy durations from three months to 12 months with automatic renewal up to 36 months and the zeroing out of the individual mandate tax penalty as having a positive impact on Health Insurance Innovations in the short-term. Sparacino says the recent pullback in shares of Health Insurance Innovations makes the valuation "particularly compelling."